MYC regulates the antitumor immune response through CD47 and PD-L1

Inflammation and cancer: back to Virchow?

Balkwill, F., & Mantovani, A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04046-0 · Cited by 7,746 · see citing works

Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion

Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474 · see citing works

Selective inhibition of BET bromodomains

Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262 · see citing works

Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential

Sharma, P., & Allison, J. P. (2015) · Cell · doi:10.1016/j.cell.2015.03.030 · Cited by 2,345 · see citing works

CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells

Majeti, R., Chao, M. P., Alizadeh, A. A., Pang, W. W., Jaiswal, S., Gibbs, K. D., van Rooijen, N., & Weissman, I. L. (2009) · Cell · doi:10.1016/j.cell.2009.05.045 · Cited by 1,752 · see citing works

CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis

Jaiswal, S., Jamieson, C. H. M., Pang, W. W., Park, C. Y., Chao, M. P., Majeti, R., Traver, D. J., van Rooijen, N., & Weissman, I. L. (2009) · Cell · doi:10.1016/j.cell.2009.05.046 · Cited by 1,578 · see citing works

Transcriptional Amplification in Tumor Cells with Elevated c-Myc

Lin, C. Y., Lovén, J., Rahl, P. B., Paranal, R. M., Burge, C. B., Bradner, J. E., Lee, T. I., & Young, R. A. (2012) · Cell · doi:10.1016/j.cell.2012.08.026 · Cited by 1,498 · see citing works

New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape

Mittal, D., Gubin, M. M., Schreiber, R. D., & Smyth, M. J. (2014) · Current Opinion in Immunology · doi:10.1016/j.coi.2014.01.004 · Cited by 1,471 · see citing works

Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours

Galon, J., Mlecnik, B., Bindea, G., Angell, H. K., Berger, A., Lagorce, C., Lugli, A., Zlobec, I., Hartmann, A., Bifulco, C. B., et al. (2013) · The Journal of Pathology · doi:10.1002/path.4287 · Cited by 1,358 · see citing works

Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma

Parsa, A. T., Waldron, J. S., Panner, A., Crane, C. A., Parney, I. F., Barry, J. J., Cachola, K. E., Murray, J. C., Tihan, T., Jensen, M. C., et al. (2006) · Nature Medicine · doi:10.1038/nm1517 · Cited by 1,341 · see citing works

Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity

Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2012) · Current Opinion in Immunology · doi:10.1016/j.coi.2011.12.009 · Cited by 1,324 · see citing works

c-MYC: more than just a matter of life and death

Pelengaris, S., Khan, M., & Evan, G. I. (2002) · Nature reviews. Cancer · doi:10.1038/nrc904 · Cited by 1,172 · see citing works

c-Myc Is a Universal Amplifier of Expressed Genes in Lymphocytes and Embryonic Stem Cells

Nie, Z., Hu, G., Wei, G., Cui, K., Yamane, A., Resch, W., Wang, R., Green, D. R., Tessarollo, L., Casellas, R. C., et al. (2012) · Cell · doi:10.1016/j.cell.2012.08.033 · Cited by 1,075 · see citing works

Reversible tumorigenesis by MYC in hematopoietic lineages.

Felsher, D., & Bishop, J. (1999) · Molecules and Cells · doi:10.1016/s1097-2765(00)80367-6 · Cited by 917 · see citing works

MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer

Shachaf, C. M., Kopelman, A. M., Arvanitis, C., Karlsson, Å., Beer, S., Mandl, S., Bachmann, M. H., Borowsky, A. D., Ruebner, B., Cardiff, R. D., et al. (2004) · Nature · doi:10.1038/nature03043 · Cited by 874 · see citing works

c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphomaPreprint

Weng, A. P., Millholland, J. M., Yashiro–Ohtani, Y., Arcangeli, M.-L., Lau, A. N., Wai, C., Bianco, C. D., Rodríguez, C. G., Sai, H., Tobias, J. W., et al. (2006) · Genes & Development · doi:10.1101/gad.1450406 · Cited by 863 · see citing works

Adoptive immunotherapy for cancer: building on success

Gattinoni, L., Powell, D. J., Rosenberg, S. A., & Restifo, N. P. (2006) · Nature reviews. Immunology · doi:10.1038/nri1842 · Cited by 841 · see citing works

Oncogene Addiction

Weinstein, I. B., & Joe, A. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-3293 · Cited by 805 · see citing works

Genome‐wide molecular profiles of HCV‐induced dysplasia and hepatocellular carcinoma†

Wurmbach, E., Chen, Y., Khitrov, G., Zhang, W., Roayaie, S., Schwartz, M., Fiel, M. I., Thung, S. N., Mazzaferro, V., Bruix, J., et al. (2007) · Hepatology · doi:10.1002/hep.21622 · Cited by 721 · see citing works

Sustained Loss of a Neoplastic Phenotype by Brief Inactivation of MYC

Jain, M., Arvanitis, C., Chu, K., Dewey, W. C., Leonhardt, E. A., Trinh, M., Sundberg, C. D., Bishop, J. M., & Felsher, D. W. (2002) · Science · doi:10.1126/science.1071489 · Cited by 647 · see citing works

The Integrated Genome Browser: free software for distribution and exploration of genome-scale datasets

Nicol, J. W., Helt, G. A., Blanchard, S. G., Raja, A. N., & Loraine, A. E. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp472 · Cited by 623 · see citing works

Induction and apoptotic regression of lung adenocarcinomas by regulation of a <i>K-Ras</i> transgene in the presence and absence of tumor suppressor genes

Fisher, G. H., Wellen, S. L., Klimstra, D., Lenczowski, J. M., Tichelaar, J. W., Lizak, M. J., Whitsett, J. A., Koretsky, A., & Varmus, H. E. (2001) · Genes &amp; Development · doi:10.1101/gad.947701 · Cited by 582 · see citing works

Innate Immune Recognition of Cancer

Woo, S., Corrales, L. P., & Gajewski, T. F. (2015) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032414-112043 · Cited by 569 · see citing works

CD4 + T Cell–Mediated Tumor Rejection Involves Inhibition of Angiogenesis that Is Dependent on IFNγ Receptor Expression by Nonhematopoietic Cells

Qin, Z., & Blankenstein, T. J. F. (2000) · Immunity · doi:10.1016/s1074-7613(00)80218-6 · Cited by 511 · see citing works

Activation and repression by oncogenic MYC shape tumour-specific gene expression profiles

Walz, S., Lorenzin, F., Morton, J. P., Wiese, K. E., von Eyß, B., Herold, S., Rycak, L., Dumay‐Odelot, H., Karim, S. A., Bartkuhn, M., et al. (2014) · Nature · doi:10.1038/nature13473 · Cited by 502 · see citing works

Primary Antitumor Immune Response Mediated by CD4+ T Cells

Corthay, A., Skovseth, D. K., Lundin, K. U., Røsjø, E., Omholt, H., Hofgaard, P. O., Haraldsen, G., & Bogen, B. (2005) · Immunity · doi:10.1016/j.immuni.2005.02.003 · Cited by 478 · see citing works

Selective transcriptional regulation by Myc in cellular growth control and lymphomagenesis

Sabò, A., Kress, T. R., Pelizzola, M., de Pretis, S., Gorski, M. M., Tesi, A., Morelli, M. J., Bora, P., Doni, M., Verrecchia, A., et al. (2014) · Nature · doi:10.1038/nature13537 · Cited by 478 · see citing works

Classification of current anticancer immunotherapies

Galluzzi, L., Vacchelli, E., Pedro, J. M. B., Buqué, A., Senovilla, L., Baracco, E. E., Bloy, N., Castoldi, F., Abastado, J., Agostinis, P., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2998 · Cited by 471 · see citing works

c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations

D'Cruz, C., Gunther, E., Boxer, R. B., Hartman, J., Sintasath, L., Moody, S., Cox, J. D., Seung, H. I., Belka, G., Golant, A., et al. (2001) · Nature Medicine · doi:10.1038/84691 · Cited by 439 · see citing works

Reversibility of acute B-cell leukaemia induced by BCR–ABL1

Huettner, C. S., Zhang, P., Etten, R. A. V., & Tenen, D. G. (2000) · Nature Genetics · doi:10.1038/71691 · Cited by 413 · see citing works

Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation

Wu, C.-H., van Riggelen, J., Yetil, A., Fan, A. C., Bachireddy, P., & Felsher, D. W. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701953104 · Cited by 405 · see citing works

Therapeutic Antibody Targeting of CD47 Eliminates Human Acute Lymphoblastic Leukemia

Chao, M. P., Alizadeh, A. A., Tang, C. Z., Jan, M., Weissman-Tsukamoto, R., Zhao, F., Park, C. Y., Weissman, I. L., & Majeti, R. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2238 · Cited by 381 · see citing works

Characterization of a Large Panel of Patient-Derived Tumor Xenografts Representing the Clinical Heterogeneity of Human Colorectal Cancer

Julien-Grille, S., Merino‐Trigo, A., Lacroix, L., Pocard, M. D., Goèré, D., Mariani, P., Landron, S., Bigot, L., Némati, F., Dartigues, P., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0372 · Cited by 360 · see citing works

CD4+ T Cells Contribute to the Remodeling of the Microenvironment Required for Sustained Tumor Regression upon Oncogene Inactivation

Rakhra, K., Bachireddy, P., Zabuawala, T., Zeiser, R., Xu, L., Kopelman, A., Fan, A. C., Yang, Q., Braunstein, L., Crosby, E., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.10.002 · Cited by 339 · see citing works

Control of cell growth by c-Myc in the absence of cell division

Schuhmacher, M., Staege, M. S., Pajic, A., Polack, A., Weidle, U. H., Bornkamm, G. W., Eick, D., & Kohlhuber, F. (1999) · Current Biology · doi:10.1016/s0960-9822(99)80507-7 · Cited by 288 · see citing works

Notch1 Contributes to Mouse T-Cell Leukemia by Directly Inducing the Expression of c-myc

Sharma, V. M., Calvo, J. A., Draheim, K., Cunningham, L. A., Hermance, N. M., Beverly, L. J., Krishnamoorthy, V., Bhasin, M., Capobianco, A. J., & Kelliher, M. A. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.01091-06 · Cited by 265 · see citing works

Interaction between B7-H1 and PD-1 determines initiation and reversal of T-cell anergy

Tsushima, F., Yao, S., Shin, T., Flies, A. S., Flies, S. J., Xu, H., Tamada, K., Pardoll, D. M., & Chen, L. (2007) · Blood · doi:10.1182/blood-2006-11-060087 · Cited by 237 · see citing works

MYC through miR-17-92 Suppresses Specific Target Genes to Maintain Survival, Autonomous Proliferation, and a Neoplastic State

Li, Y., Choi, P. S., Casey, S. C., Dill, D. L., & Felsher, D. W. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.06.014 · Cited by 174 · see citing works

Cell-Type Independent MYC Target Genes Reveal a Primordial Signature Involved in Biomass Accumulation

Ji, H., Wu, G. Y., Zhan, X., Nolan, A., Koh, C. M., Marzo, A. D., Doan, H. M., Fan, J., Cheadle, C., Fallahi, M., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026057 · Cited by 162 · see citing works

Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch

Giuriato, S., Ryeom, S. W., Fan, A. C., Bachireddy, P., Lynch, R. C., Rioth, M. J., van Riggelen, J., Kopelman, A. M., Passegue, E. A., Tang, F. L. M., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0608017103 · Cited by 149 · see citing works

Thrombospondin-1 Signaling through CD47 Inhibits Self-renewal by Regulating c-Myc and Other Stem Cell Transcription Factors

Kaur, S., Soto‐Pantoja, D. R., Stein, E. V., Liu, C., ELKAHLOUN, A. G., Pendrak, M. L., Nicolae, A., SINGH, S. P., Nie, Z., Levens, D., et al. (2013) · Scientific Reports · doi:10.1038/srep01673 · Cited by 138 · see citing works

Taming of the beast: shaping Myc-dependent amplification

Wolf, E., Lin, C. Y., Eilers, M., & Levens, D. (2014) · Trends in Cell Biology · doi:10.1016/j.tcb.2014.10.006 · Cited by 135 · see citing works

Experimental mouse tumour models: what can be learnt about human cancer immunology?

Dranoff, G. (2011) · Nature reviews. Immunology · doi:10.1038/nri3129 · Cited by 132 · see citing works

Conditional gene expression in secretory tissues and skin of transgenic mice using the MMTV‐LTR and the tetracycline responsive system

Hennighausen, L. G., Wall, R. J., Tillmann, U., Li, M., & Furth, P. A. (1995) · Journal of Cellular Biochemistry · doi:10.1002/jcb.240590407 · Cited by 124 · see citing works

The E2F3-Oncomir-1 Axis Is Activated in Wilms' Tumor

Kort, E. J., Farber, L. J., Tretiakova, M., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0592 · Cited by 115 · see citing works

The Role of MIZ-1 in MYC-Dependent TumorigenesisPreprint

Wiese, K. E., Walz, S., von Eyß, B., Wolf, E., Athineos, D., Sansom, O. J., & Eilers, M. (2013) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a014290 · Cited by 111 · see citing works

CD8 T Cell Help for Innate Antitumor Immunity

Shanker, A., Verdeil, G., Buferne, M., Inderberg, E. M., Puthier, D., Joly, F., Nguyen, C., Leserman, L., Auphan‐Anezin, N., & Schmitt‐Verhulst, A. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.10.6651 · Cited by 101 · see citing works

Reversible lymphomagenesis in conditionally c‐MYC expressing mice

Marinković, D., Marinković, T., Mahr, B., Heß, J., & Wirth, T. C. (2004) · International Journal of Cancer · doi:10.1002/ijc.20099 · Cited by 79 · see citing works

T cell stimulation via CD47: agonistic and antagonistic effects of CD47 monoclonal antibody 1/1A4

Waclavicek, M., Majdic, O., Stulnig, T. M., et al. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.159.11.5345 · Cited by 68 · see citing works

Role of CD47 in the Induction of Human Naive T Cell Anergy

Avice, M.-N., Rubio, M., Sergerie, M., Delespesse, G., & Sarfati, M. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.5.2459 · Cited by 52 · see citing works

Anti–PD-1 Therapy in Melanoma

Moreno, B. H., Parisi, G., Robert, L., & Ribas, A. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.02.008 · Cited by 49 · see citing works

Time-Dependent c-Myc Transactomes Mapped by Array-Based Nuclear Run-On Reveal Transcriptional Modules in Human B Cells

Fan, J., Zeller, K. I., Chen, Y.-C., Watkins, T., Barnes, K. C., Becker, K. G., Dang, C. V., & Cheadle, C. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009691 · Cited by 36 · see citing works

In vitro culture of human acute lymphoblastic leukemia (ALL) cells in serum-free media; a comparison of native ALL blasts, ALL cell lines and virus-transformed B cell lines

Bruserud, Ø., Glenjen, N. I., Ryningen, A., et al. (2003) · Leukemia Research · doi:10.1016/s0145-2126(02)00227-8 · Cited by 26 · see citing works

Array-Based Nuclear Run-On Analysis

Fan, J., Chen, Y., Watkins, T., Dang, C. V., Gorospe, M., & Cheadle, C. (2011) · Methods in molecular biology · doi:10.1007/978-1-61779-376-9_33 · Cited by 7 · see citing works

Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy

Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588 · see citing works

Diversity, Mechanisms, and Significance of Macrophage Plasticity

Locati, M., Curtale, G., & Mantovani, A. (2020) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-012418-012718 · Cited by 2,199 · see citing works

Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory

Poggio, M., Hu, T., Pai, C.-C., Chu, B., Belair, C. D., Chang, A., Montabana, E., Lang, U. E., Fu, Q., Fong, L., et al. (2019) · Cell · doi:10.1016/j.cell.2019.02.016 · Cited by 1,376 · see citing works

Cyclin D–CDK4 kinase destabilizes PD-L1 via cullin 3–SPOP to control cancer immune surveillance

Zhang, J., Bu, X., Wang, H., Zhu, Y., Geng, Y., Nihira, N. T., Tan, Y., Ci, Y., Wu, F., Dai, X., et al. (2018) · Nature · doi:10.1038/nature25015 · Cited by 1,013 · see citing works

Tumor Microenvironment Characterization in Gastric Cancer Identifies Prognostic and Immunotherapeutically Relevant Gene Signatures

Zeng, D., Li, M., Zhou, R., Zhang, J., Sun, H., Shi, M., Bin, J., Liao, Y., Rao, J., & Liao, W. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0436 · Cited by 986 · see citing works

Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments

Kumagai, S., Koyama, S., Itahashi, K., Tanegashima, T., Lin, Y.-T., Togashi, Y., Kamada, T., Irie, T., Okumura, G., Kono, H., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.01.001 · Cited by 892 · see citing works

Identification of CMTM6 and CMTM4 as PD-L1 protein regulators

Mezzadra, R., Sun, C., Jae, L. T., Gomez-Eerland, R., de Vries, E., Wu, W., Logtenberg, M. E. W., Slagter, M., Rozeman, E. A., Hofland, I., et al. (2017) · Nature · doi:10.1038/nature23669 · Cited by 697 · see citing works

Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA

Coelho, M. A., de Carné Trécesson, S., Rana, S., Zecchin, D., Moore, C., Molina-Arcas, M., East, P., Spencer-Dene, B., Nye, E., Barnouin, K., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.11.016 · Cited by 653 · see citing works

Regulation of PD-L1 expression in the tumor microenvironment

Yi, M., Niu, M., Xu, L., Luo, S., & Wu, K. (2021) · Journal of Hematology &amp; Oncology · doi:10.1186/s13045-020-01027-5 · Cited by 681 · see citing works

Challenges and Opportunities for Pancreatic Cancer Immunotherapy

Bear, A. S., Vonderheide, R. H., & O'Hara, M. H. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.08.004 · Cited by 674 · see citing works

Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors

Grosser, R., Cherkassky, L., Chintala, N., & Adusumilli, P. S. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.09.006 · Cited by 603 · see citing works

Myc Cooperates with Ras by Programming Inflammation and Immune Suppression

Kortlever, R. M., Sodir, N. M., Wilson, C. H., Burkhart, D. L., Pellegrinet, L., Brown Swigart, L., Littlewood, T. D., & Evan, G. I. (2017) · Cell · doi:10.1016/j.cell.2017.11.013 · Cited by 553 · see citing works

Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer

Topper, M. J., Vaz, M., Chiappinelli, K. B., DeStefano Shields, C. E., Niknafs, N., Yen, R.-W. C., Wenzel, A., Hicks, J., Ballew, M., Stone, M., et al. (2017) · Cell · doi:10.1016/j.cell.2017.10.022 · Cited by 537 · see citing works

Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade

Johnson, D. B., Frampton, G. M., Rioth, M. J., Yusko, E., Xu, Y., Guo, X., Ennis, R. C., Fabrizio, D., Chalmers, Z. R., Greenbowe, J., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0143 · Cited by 481 · see citing works

Differentiation therapy revisited

de Thé, H. (2018) · Nature reviews. Cancer · doi:10.1038/nrc.2017.103 · Cited by 462 · see citing works

Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas

Schaub, F. X., Dhankani, V., Berger, A. C., Trivedi, M., Richardson, A. B., Shaw, R., Zhao, W., Zhang, X., Ventura, A., Liu, Y., et al. (2018) · Cell Systems · doi:10.1016/j.cels.2018.03.003 · Cited by 431 · see citing works

The emerging role of epigenetic therapeutics in immuno-oncology

Topper, M. J., Vaz, M., Marrone, K. A., Brahmer, J. R., & Baylin, S. B. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0266-5 · Cited by 433 · see citing works

Innate immune signaling and regulation in cancer immunotherapy

Corrales, L., Matson, V., Flood, B., Spranger, S., & Gajewski, T. F. (2017) · Cell Research · doi:10.1038/cr.2016.149 · Cited by 408 · see citing works

High response rate to PD-1 blockade in desmoplastic melanomas

Eroglu, Z., Zaretsky, J. M., Hu-Lieskovan, S., Kim, D. W., Algazi, A., Johnson, D. B., Liniker, E., Kong, B., Munhoz, R., Rapisuwon, S., et al. (2018) · Nature · doi:10.1038/nature25187 · Cited by 338 · see citing works

Target gene-independent functions of MYC oncoproteins

Baluapuri, A., Wolf, E., & Eilers, M. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-0215-2 · Cited by 310 · see citing works

Chemotherapy induces enrichment of CD47 ⁺ /CD73 ⁺ /PDL1 ⁺ immune evasive triple-negative breast cancer cells

Samanta, D., Park, Y., Ni, X., Li, H., Zahnow, C. A., Gabrielson, E., Pan, F., & Semenza, G. L. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1718197115 · Cited by 302 · see citing works

Translation control of the immune checkpoint in cancer and its therapeutic targeting

Xu, Y., Poggio, M., Jin, H. Y., Shi, Z., Forester, C. M., Wang, Y., Stumpf, C. R., Xue, L., Devericks, E., So, L., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0321-2 · Cited by 261 · see citing works

The Extrinsic and Intrinsic Roles of PD‐L1 and Its Receptor PD‐1: Implications for Immunotherapy Treatment

Hudson, K., Cross, N., Jordan-Mahy, N., & Leyland, R. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.568931 · Cited by 243 · see citing works

Enhancing CRISPR/Cas gene editing through modulating cellular mechanical properties for cancer therapy

Zhang, D., Wang, G., Yu, X., Wei, T., Farbiak, L., Johnson, L. T., Taylor, A. M., Xu, J., Hong, Y., Zhu, H., et al. (2022) · Nature Nanotechnology · doi:10.1038/s41565-022-01122-3 · Cited by 243 · see citing works

Cellular senescence: Immunosurveillance and future immunotherapy

Burton, D. G. A., & Stolzing, A. (2018) · Ageing Research Reviews · doi:10.1016/j.arr.2018.02.001 · Cited by 221 · see citing works

Dinaciclib induces immunogenic cell death and enhances anti-PD1-mediated tumor suppression

Hossain, D. M. S., Javaid, S., Cai, M., Zhang, C., Sawant, A., Hinton, M., Sathe, M., Grein, J., Blumenschein, W., Pinheiro, E. M., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci94586 · Cited by 216 · see citing works

<i>TP53</i> mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype

Sallman, D. A., McLemore, A. F., Aldrich, A. L., Komrokji, R. S., McGraw, K. L., Dhawan, A., Geyer, S., Hou, H.-A., Eksioglu, E. A., Sullivan, A., et al. (2020) · Blood · doi:10.1182/blood.2020006158 · Cited by 196 · see citing works

Exercise enhances skeletal muscle regeneration by promoting senescence in fibro-adipogenic progenitors

Saito, Y., Chikenji, T. S., Matsumura, T., Nakano, M., & Fujimiya, M. (2020) · Nature Communications · doi:10.1038/s41467-020-14734-x · Cited by 196 · see citing works

Genomic instability, inflammatory signaling and response to cancer immunotherapy

Chen, M., Linstra, R., & van Vugt, M. A. T. M. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188661 · Cited by 166 · see citing works

Activation of JUN in fibroblasts promotes pro-fibrotic programme and modulates protective immunity

Cui, L., Chen, S.-Y., Lerbs, T., Lee, J.-W., Domizi, P., Gordon, S., Kim, Y.-H., Nolan, G., Betancur, P., & Wernig, G. (2020) · Nature Communications · doi:10.1038/s41467-020-16466-4 · Cited by 153 · see citing works

PRDM1/BLIMP1 induces cancer immune evasion by modulating the USP22-SPI1-PD-L1 axis in hepatocellular carcinoma cells

Li, Q., Zhang, L., You, W., Xu, J., Dai, J., Hua, D., Zhang, R., Yao, F., Zhou, S., Huang, W., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-35469-x · Cited by 128 · see citing works

Stromal fibroblasts mediate anti-PD-1 resistance via MMP-9 and dictate TGFβ inhibitor sequencing in melanoma

Zhao, F., Evans, K., Xiao, C., DeVito, N., Theivanthiran, B., Holtzhausen, A., Siska, P. J., Blobe, G. C., & Hanks, B. A. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0086 · Cited by 117 · see citing works

Gemcitabine nanoparticles promote antitumor immunity against melanoma

Zhang, Y., Bush, X., Yan, B., & Chen, J. A. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2018.10.022 · Cited by 117 · see citing works

HDAC3 inhibition upregulates PD-L1 expression in B-cell lymphomas and augments the efficacy of anti-PD-L1 therapy

Deng, S., Hu, Q., Zhang, H., Yang, F., Peng, C., & Huang, C. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-1068 · Cited by 116 · see citing works

Scalable genetic screening for regulatory circuits using compressed Perturb-seq

Yao, D., Binan, L., Bezney, J., Simonton, B., Freedman, J., Frangieh, C. J., Dey, K., Geiger-Schuller, K., Eraslan, B., Gusev, A., et al. (2024) · Nature Biotechnology · doi:10.1038/s41587-023-01964-9 · Cited by 101 · see citing works

Mutant p53 drives cancer chemotherapy resistance due to loss of function on activating transcription of PUMA

Huang, Y., Liu, N., Liu, J., Liu, Y., Zhang, C., Long, S., Luo, G., Zhang, L., & Zhang, Y. (2019) · Cell Cycle · doi:10.1080/15384101.2019.1688951 · Cited by 94 · see citing works

Omomyc Reveals New Mechanisms To Inhibit the MYC Oncogene

Demma, M. J., Mapelli, C., Sun, A., Bodea, S., Ruprecht, B., Javaid, S., Wiswell, D., Muise, E., Chen, S., Zelina, J., et al. (2019) · Molecular and Cellular Biology · doi:10.1128/mcb.00248-19 · Cited by 92 · see citing works

Regulatory mechanisms of PD-L1 expression in cancer cells

Shi, Y. (2018) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-018-2226-9 · Cited by 92 · see citing works

Extracellular vesicle PD‐L1 in reshaping tumor immune microenvironment: biological function and potential therapy strategies

Liu, J., Peng, X., Yang, S., Li, X., Huang, M., Wei, S., Zhang, S., He, G., Zheng, H., Fan, Q., et al. (2022) · Cell Communication and Signaling · doi:10.1186/s12964-021-00816-w · Cited by 75 · see citing works

Trial watch: immune checkpoint blockers for cancer therapy

Vanpouille-Box, C., Lhuillier, C., Bezu, L., Aranda, F., Yamazaki, T., Kepp, O., Fucikova, J., Spisek, R., Demaria, S., Formenti, S. C., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1373237 · Cited by 73 · see citing works

BET Bromodomain Proteins as Cancer Therapeutic Targets

Shu, S., & Polyak, K. (2016) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2016.81.030908 · Cited by 72 · see citing works

<i>Max</i> deletion destabilizes MYC protein and abrogates Eµ- <i>Myc</i> lymphomagenesis

Mathsyaraja, H., Freie, B., Cheng, P.-F., Babaeva, E., Catchpole, J. T., Janssens, D., Henikoff, S., & Eisenman, R. N. (2019) · Genes &amp; Development · doi:10.1101/gad.325878.119 · Cited by 54 · see citing works

Epigenetic mechanisms of tumor resistance to immunotherapy

Arenas-Ramirez, N., Sahin, D., & Boyman, O. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2908-7 · Cited by 36 · see citing works

Solving the Puzzle of Immune Tolerance for β-Cell Replacement Therapy for Type 1 Diabetes

Bluestone, J. A., & Tang, Q. (2020) · Cell Stem Cell · doi:10.1016/j.stem.2020.09.008 · Cited by 16 · see citing works

MYC Activity Inference Captures Diverse Mechanisms of Aberrant MYC Pathway Activation in Human Cancers

Schaafsma, E., Zhao, Y., Zhang, L., Li, Y., & Cheng, C. (2021) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-20-0526 · Cited by 12 · see citing works

Predictive Biomarkers for PD-1 and PD-L1 Immune Checkpoint Blockade Therapy

Song, Y., Li, Z., Xue, W., & Zhang, M. (2019) · Immunotherapy · doi:10.2217/imt-2018-0173 · Cited by 21 · see citing works

CD47 blockade as another immune checkpoint therapy for cancer

Vonderheide, R. H. (2015) · Nature Medicine · doi:10.1038/nm.3965 · Cited by 131 · see citing works

Detailed characterization of PD-1/PD-L1 and CTLA4 expression and tumor-infiltrating lymphocytes in yolk sac tumorsPreprint

Xu, H., Zhang, D., Zhao, C. H., Qin, L., Wei, R., Xi, L., & Li, F. (2022) · Research Square · doi:10.21203/rs.3.rs-1765232/v1

Immune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies

Ilcus, C., Bagacean, C., Tempescul, A., Popescu, C., Pârvu, A. V., Cenariu, M., Bocșan, I. C., & Zdrenghea, M. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s133385 · Cited by 42 · see citing works

Immune checkpoint blockade as a potential therapeutic strategy for undifferentiated malignancies

Devereaux, K. A., Charu, V., Zhao, S., Charville, G. W., Bangs, C. D., van de Rijn, M., Cherry, A. M., & Natkunam, Y. (2018) · Human Pathology · doi:10.1016/j.humpath.2018.06.034 · Cited by 6 · see citing works